CD8A and neoplasm: Furthermore, VB124, a highly potent inhibitor specifically targeting MCT4 suppresses tumor immune activity by promoting CD8+T cell infiltration and augmenting cytotoxicity, thus improving the efficacy of anti-PD-1 therapy in drug-resistant cancer xenograft models89.